• Cy3 NHS ester (non-sulfonated): Practical Labeling Guide

  2026-09-30

  Cy3 NHS ester (non-sulfonated) provides an orange-emitting NHS ester for fluorescent labeling of accessible amino groups in proteins, peptides, and oligonucleotides. It is appropriate for workflows that can tolerate a DMSO or DMF co-solvent, but it should not be selected for water-only reactions or especially solvent-sensitive biomolecules when a sulfonated, water-soluble alternative is required.

• DiR for EV Biodistribution and MPS Evasion

  2026-09-30

  Extracellular vesicle therapies need more than therapeutic cargo: they require interpretable biodistribution data. This thought-leadership article explains how DiR (DiIC 18 (7)) can map membrane-associated EV fate, test the Engage & Evasion strategy described for ischemic disease, and strengthen translational decisions while respecting the probe’s interpretive limitations.

• Lysosomal ADMA Signaling and Lipid Homeostasis

  2026-09-29

  The reference study identifies asymmetric dimethylarginine (ADMA) as a lysosome-derived signaling metabolite that links proteolysis, organelle communication, lipid-droplet dynamics, and tissue pathology. Its integrated plasma and single-lysosome metabolomics approach suggests that impaired ADMA export in cystinosis contributes to lipid accumulation, oxidative injury, and cell death, while restoring cytosolic ADMA improves cellular homeostasis.

• 4-Hydroxytamoxifen: Protocol and QC Guide

  2026-09-29

  4-Hydroxytamoxifen is a DMSO-compatible estrogen receptor modulator for controlled cell and tissue research workflows, including breast cancer research, prostate cancer research, apoptosis assays, and cardiac myocyte calcium handling studies. It should not be selected for protocols requiring water- or ethanol-based solubilization, and prepared solutions should not be stored long term.

• ECL Western Blotting Substrate: Practical Guide

  2026-09-28

  ECL Western Blotting Substrate is a luminol-based, nonradioactive horseradish peroxidase detection reagent for sensitive protein detection by chemiluminescence in immunoblots. It is intended for HRP-based Western blot workflows using X-ray film or CCD imaging, not for fluorescent or radioisotopic detection.

• Cisplatin Workflows for DNA Repair and Resistance

  2026-09-28

  Use Cisplatin (CDDP) to connect DNA damage, repair signaling, and cell-death readouts in cancer research. A nasopharyngeal carcinoma study points to a practical sensitization workflow: compare cisplatin alone with 3-MA combination treatment using viability, apoptosis, and DNA-damage assays—while controlling carefully for solvent and 3-MA’s multiple effects.

• Erastin (B1524): Practical Ferroptosis Assay Guide

  2026-09-27

  A scenario-based guide to using Erastin (SKU B1524) in ferroptosis research, with practical guidance on model selection, dosing, solution handling, and interpretation. It distinguishes an initial treatment condition from a validated result and links oxidative-stress context to the relevant literature.

• Propranolol in Burn Metabolism Research

  2026-09-26

  Use Propranolol to probe how non-selective β-adrenergic blockade connects cardiovascular regulation with adipose-tissue metabolism. A burn-injury trial offers a translational framework for choosing lipidomic, metabolic, and signaling readouts—while practical workflow guidance helps separate drug effects from solvent and assay artifacts.

• Cy3 Rabbit Anti-Goat IgG (H+L) Antibody Guide

  2026-09-25

  The Cy3 Rabbit Anti-Goat IgG (H+L) Antibody provides fluorescent detection of goat IgG primary antibodies in ICC/IF, IHC, flow cytometry, and fluorescence-readout ELISA workflows. It is not a general secondary for non-goat primaries, and its Cy3 signal should not be treated as a substitute for an enzyme-based ELISA readout.

• DiR Membrane Imaging for Pancreatic Nanomedicine

  2026-09-25

  DiR (DiIC 18 (7)) offers a way to visualize membrane-associated signals in cell and tissue assays. This article explains how membrane imaging can complement, but not substitute for, biodistribution and therapeutic readouts in acute pancreatitis nanomedicine research.

• HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit Plus

  2026-09-24

  This kit supports in vitro transcription of randomly Cy3-modified RNA probes for fluorescence-based detection when unlabeled transcripts are not suitable. It is intended for research workflows such as in situ hybridization and Northern blotting, not diagnostic, clinical, or therapeutic use.

• TAI-1: Hec1 Inhibitor Evidence and Research Use

  2026-09-24

  TAI-1 is a potent Hec1 inhibitor reported to disrupt Hec1–Nek2 interaction and inhibit cancer-cell growth. Its reported K562 GI50 is 13.48 nM, while study conditions and several translational details are not specified in the product dossier.

• Phosphorylated H1 Supports Repair at Stalled Replication For

  2026-09-23

  The study identifies S-phase-phosphorylated linker histone H1 as a regulator of repair at collapsed replication forks, linking its assembly with single-stranded DNA to interactions with repair factors including HPF1. Mutant comparisons, site-specific photocrosslinking, and cellular experiments support a model in which phosphorylated H1 helps organize repair-factor activity, while leaving important questions about mechanism and generalizability open.

• Cytochalasin B: Reliable Cytoskeletal Assays

  2026-09-23

  Learn how Cytochalasin B (SKU C4939) can help researchers distinguish actin-dependent biology from assay artifacts, optimize handling, and interpret viability or cytotoxicity data more reliably. This scenario-based guide covers experimental design, protocol controls, orthogonal readouts, and practical vendor-selection criteria.

• GSH-Responsive MOF Nanoparticles for Melanoma Therapy

  2026-09-22

  The reference study developed ICG-MOF-SS-AUNP12, a metal–organic framework nanoparticle that combines photothermal ablation with glutathione-responsive PD-1/PD-L1 checkpoint blockade. Its design links near-infrared heating, tumor-microenvironment-responsive release, and immune activation, providing a rationale for combination treatment rather than relying on photothermal therapy alone.

8060 records 1/538 page Next 12345 下5页 Last page